A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL).

被引：0
|
作者：
Li, Jianyong
Zhou, Keshu
Nian, Weiqi
Cui, Guohui
Wang, Jishi
Zhang, Xiaoping
Cen, Hong
Li, Fei
Yi, Shuhua
Feng, Ru
Xu, Chongyuan
Qian, Wenbin
Liu, Lihong
Li, Caixia
Zhao, Xielan
Chen, Zi
Qiao, Junxiao
Zhang, Hongli
Ahmad, Mohammad
Zhai, Yifan
机构：
[1] Jiangsu Prov Hosp, Nanjing, Peoples R China
[2] Henan Canc Hosp, Zhengzhou, Peoples R China
[3] Chongqing Canc Hosp, Chongqing, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[5] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China
[6] Southeast Univ, Zhongda Hosp, Nanjing, Peoples R China
[7] Guangxi Med Univ, Dept Med Oncol, Affiliated Canc Hosp, Nanning, Peoples R China
[8] Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China
[9] Chinese Acad Med Sci, Hematol Hosp, Beijing, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[11] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Hangzhou, Peoples R China
[12] Hebei Med Univ, Tumor Hosp Hebei Prov, Hosp 4, Shijiazhuang, Peoples R China
[13] Suzhou First Peoples Hosp, Suzhou, Peoples R China
[14] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China
[15] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[16] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7543
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase I/II study of SPC2996, an RNA antagonist of Bcl-2, in patients with advanced chronic lymphocytic leukemia (CLL)
    Tilly, H.
    Coiffier, B.
    Michallet, A. S.
    Radford, J. A.
    Geisler, C. H.
    Gadeberg, O.
    Dalseg, A.
    Steenken, E. J.
    Dalby, L. Worsaae
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Bendamustine plus Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study
    Chang, Julie E.
    Zhang, Chong
    Kim, KyungMann
    Kirby, Rachel
    Volk, Lynn
    Werndli, Jae
    Go, Ronald S.
    Weiss, Matthias
    Blank, Jules H.
    Thompson, Michael A.
    Farnen, John P.
    Cole, Craig E.
    Bseiso, Ali W.
    Volk, Michael
    Bayer, Gerald
    Wassenaar, Tim
    Mansky, Patrick
    Traynor, Anne
    Fenske, Timothy S.
    Kahl, Brad S.
    BLOOD, 2012, 120 (21)
  • [43] Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Danilov, Alexey V.
    Lam, Vi
    Bria, Thurlow
    Spurgeon, Stephen E.
    Park, Byung
    Orand, Kirsten
    Kittai, Adam S.
    BLOOD, 2021, 138
  • [44] Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Lavie, David
    Ozcan, Muhit
    Chaudhry, Arvind
    Zhou, Xuan
    Paydar, Ima
    Farooqui, Mohammed Z. H.
    Ghia, Paolo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S353 - S353
  • [45] A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Shouse, Geoffrey
    Chen, Lu
    Siddiqi, Tanya
    Muir, Alex
    Brown, Jennifer R.
    Spurgeon, Stephen E.
    Danilov, Alexey V.
    LEUKEMIA & LYMPHOMA, 2024, 65 (10) : 1516 - 1519
  • [46] Genasense (Bcl-2 antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Phase 1 and 2 results.
    Rai, KR
    O'Brien, S
    Cunningham, C
    Turkina, AG
    Ochoa, L
    Frankel, SR
    Golenkov, AK
    BLOOD, 2002, 100 (11) : 384A - 384A
  • [47] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Van Den Neste, Eric
    Cazin, Bruno
    Janssens, Ann
    Gonzalez-Barca, Eva
    Jose Terol, Maria
    Levy, Vincent
    Perez de Oteyza, Jaime
    Zachee, Pierre
    Saunders, Andrew
    de Frias, Merce
    Campas, Clara
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (03) : 581 - 591
  • [48] Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
    Eric Van Den Neste
    Bruno Cazin
    Ann Janssens
    Eva González-Barca
    María José Terol
    Vincent Levy
    Jaime Pérez de Oteyza
    Pierre Zachee
    Andrew Saunders
    Mercè de Frias
    Clara Campàs
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 581 - 591
  • [49] Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have. Undergone Prior Allogeneic Stem Cell Transplant
    Miklos, David B.
    Coutre, Steven
    O'Brien, Susan
    Byrd, John C.
    Hillmen, Peter
    Brown, Jennifer R.
    Dyer, Martin
    Mato, Anthony R.
    Keating, Michael
    Zhou, Cathy
    Fardis, Maria
    Styles, Lori
    Jaglowski, Samantha
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S82 - S83
  • [50] Efficacy and safety of ibrutinib in Chinese patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and hepatitis B virus reactivation: a post-hoc analysis
    Yang, Shenmiao
    Zhu, Rong
    Feng, Yu
    Zuo, Rui
    Huang, Xiaojun
    LEUKEMIA & LYMPHOMA, 2020, 61 : 102 - 104
12345